Consequently, mitochondria‐enriched CD8+ T cells exhibit superior antitumor efficacy and prolong survival in tumor‐bearing models.[79] Moreover, mitochondrial transfer inhibition has been shown to prevent cancer cells from hijacking mitochondria from immune cells, thus potentiating antitumor immunity. This evidence concerns the gene CD8A and neoplasm.